Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SHPH
SHPH | US
1.02
USD-0.01
-0.97%
SHPH | US
About SHPH
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
17/04/2026
Close
1.02
Open
1.01
High
1.02
Low
0.96
Shuttle Pharmaceuticals Holdings Inc. a clinical stage pharmaceutical company develops novel therapies to cure cancers. It develops Ropidoxuridine an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161 an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225 a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303 a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville Maryland.
View LessSHPH | US
Risk
172.9
Sharpe
-0.71
Luna's Score
37/100
Recommendation
Sell
Luna says (SHPH | US)
What's Working
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
113.6%1 month
172.9%3 months
155.9%6 months
141.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.37
Debt to equity
1.44
Debt to assets
0.41
Ent. to EBITDA
-0.67
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-5.74M
MarketCap
3.01M
MarketCap(USD)
3.01M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-186.00
Short ratio
0.03
Short perc.
1.94
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.54
Range1M
0.69
Range3M
3.94
Volumes: Market Activity
Rel. volume
0.27
Price X volume
74.05K
